News

Fasenra (benralizumab) and Nucala (mepolizumab) appear to be equally safe and effective in helping adults with eosinophilic granulomatosis with polyangiitis (EGPA) achieve disease remission, according to a real-world study in Europe that directly compared the two approved therapies. Still, at one year, AstraZeneca’s Fasenra was associated with…

Adding Tavneos (avacopan) to standard treatment for the two main types of ANCA-associated vasculitis (AAV) results in fewer adverse events — including a lesser number of serious side effects and infections — in adults with granulomatosis with polyangiitis, or GPA, and microscopic polyangiitis, known as MPA. That’s according…

Elevated levels in the blood of ferritin, a protein that binds to iron and stores it for use by the body, are linked to more severe damage in people with active ANCA-associated vasculitis (AAV), and to a poorer outlook for the kidneys, according to a new study from China.

Blood levels of a signaling molecule called growth differentiation factor 15 (GDF15) at diagnosis may help predict poor outcomes, including kidney failure and death, in people with ANCA-associated vasculitis (AAV), according to a study in South Korea. Data also showed that GDF15 levels were significantly associated with AAV…

Testing for the presence of specific self-reactive antibodies linked to ANCA-associated vasculitis (AAV) may help doctors more easily tell microscopic polyangiitis (MPA) from granulomatosis with polyangiitis (GPA), the two most common types of AAV, a study showed. Classifying patients as MPA or GPA based on the different types…

People with ANCA-associated vasculitis (AAV) have significantly higher blood levels of C4d, a protein that reflects activation of the classic or lectin complement pathways of the immune system, a study in Sweden suggests. Patients with self-reactive antibodies, called ANCAs, against the proteinase-3 (PR3) protein had significantly higher blood Cd4…

The U.S. Patent and Trademark Office (USPTO) has granted Conduit Pharmaceuticals a patent for AZD1656, its experimental therapy for ANCA-associated vasculitis (AAV) and other autoimmune diseases. The USPTO granted a composition of matter patent, which is a type of patent that relates to novel compounds made from two or…

Long-term treatment with Nucala (mepolizumab) — approved for use in EGPA, or eosinophilic granulomatosis with polyangiitis, the rarest type of ANCA-associated vasculitis — appears to be well tolerated by most patients, and was seen to reduce or even eliminate corticosteroid use. That’s according to new data from an…

Adding Tavneos (avacopan) to standard treatment is as safe and effective in older people with ANCA-associated vasculitis (AAV) as it is among younger patients, according to the findings of a post-hoc analysis of clinical trial data. The approved oral therapy “showed similar efficacy and safety results in patients…

Disease symptoms among people with ANCA-associated vasculitis (AAV) were found to vary by age at diagnosis and biological sex, according to data from more than 1,100 Scandinavian patients. “We identified significant differences in clinical presentation of the disease between female and male patients and between patients with a young…